Jaeeun Seong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jaeeun Seong has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Jin Young Ahn
Division of Infectious Diseases, Department of Internal Medicine and AIDS Research Institute, Yonsei University Health System, Yonsei University College of Medicine, Seoul, Korea
3 shared publications - Joon-Sup Yeom
Division of Infectious Diseases, Department of Internal Medicine and AIDS Research Institute, Yonsei University Health System, Yonsei University College of Medicine, Seoul, Korea
3 shared publications - Jun Yong Choi
Division of Infectious Diseases, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
3 shared publications - Jung Ah Lee
Division of Infectious Diseases, Department of Internal Medicine, Yonsei University College of Medicine, Seoul 03722, Republic of Korea
3 shared publications - Jung Ho Kim
Division of Infectious Diseases, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
3 shared publications - Nam Su Ku
Division of Infectious Diseases, Department of Internal Medicine and AIDS Research Institute, Yonsei University Health System, Yonsei University College of Medicine, Seoul, Korea
3 shared publications
Latest Publications
- Open Access
- 15 July 2026
- Published by MDPI AG in Journal of Fungi
- Vol. 12 (7) , 519
Risk Factors for Mortality in Candida auris Bloodstream Infection: A Multicenter Study in South Korea, 2018–2025
Candida auris (C. auris) is a multidrug-resistant pathogen that spreads clonally in healthcare settings and was designated an urgent threat by the Centers for Disease Control and Prevention in 2019. We conducted a multicenter study to identify mortality risk factors in C. auris bloodstream infection (BSI) in South Korea. In this retrospective cohort study across three tertiary centers, 50 adults with first-episode C. auris BSI were analyzed. Primary and secondary outcomes were 30- and 90-day mortality. 30-day mortality was 24%, and 90-day mortality was 46%. Older age and higher Sequential Organ Failure Assessment score were independently associated with 30-day mortality. Microbiologic clearance within 30 days was protective. For 90-day mortality, older age was the only independent risk factor, and microbiologic clearance within 90 days was also protective. In conclusion, C. auris BSI causes substantial 30-day mortality, underscoring the need for risk-stratified, clearance-focused management.
- 15 July 2026
- Published by MDPI AG in Journal of Fungi
- Vol. 12 (7) , 519
Open AccessRisk Factors for Mortality in Candida auris Bloodstream Infection: A Multicenter Study in South Korea, 2018–2025
Candida auris (C. auris) is a multidrug-resistant pathogen that spreads clonally in healthcare settings and was designated an urgent threat by the Centers for Disease Control and Prevention in 2019. We conducted a multicenter study to identify mortality risk factors in C. auris bloodstream infection (BSI) in South Korea. In this retrospective cohort study across three tertiary centers, 50 adults with first-episode C. auris BSI were analyzed. Primary and secondary outcomes were 30- and 90-day mortality. 30-day mortality was 24%, and 90-day mortality was 46%. Older age and higher Sequential Organ Failure Assessment score were independently associated with 30-day mortality. Microbiologic clearance within 30 days was protective. For 90-day mortality, older age was the only independent risk factor, and microbiologic clearance within 90 days was also protective. In conclusion, C. auris BSI causes substantial 30-day mortality, underscoring the need for risk-stratified, clearance-focused management.
- Open Access
Respiratory Microbiome of Carbapenem-Resistant Acinetobacter baumannii Ventilator-Associated Pneumonia: A Pilot Study from the Republic of Korea
Ventilator-associated pneumonia (VAP) is one of the most common hospital-acquired infections. Several studies have explored the potential role of the lung microbiome as a biomarker for identifying and predicting the prognosis of VAP. However, research on the respiratory microbiome in individuals with VAP caused by carbapenem-resistant Acinetobacter baumannii (CRAB) remains limited. Therefore, we aimed to analyze the respiratory microbiome of patients with CRAB VAP. Respiratory specimens were collected from patients who developed CRAB VAP. Microbiome diversity and composition were analyzed using 16S rRNA gene pyrosequencing. Patients were categorized into two groups based on mortality outcomes: intensive care unit (ICU) mortality or 28-day mortality after ICU discharge. Twenty patients with CRAB VAP were enrolled, including nine in the mortality group. No significant differences were observed in α-diversity indices between the study groups. However, multivariable Firth’s logistic regression revealed a significant association between a relative abundance of the Enterococcus genus ≥ 1% and mortality outcomes (odds ratio: 0.06; 95% confidence interval: 0.00–0.771; p = 0.029). This study characterized the respiratory microbiome of patients with CRAB VAP and highlighted the potential role of microbiome analysis in predicting disease prognosis. Further studies with larger sample sizes are warranted to validate these findings.
Open AccessRespiratory Microbiome of Carbapenem-Resistant Acinetobacter baumannii Ventilator-Associated Pneumonia: A Pilot Study from the Republic of Korea
Ventilator-associated pneumonia (VAP) is one of the most common hospital-acquired infections. Several studies have explored the potential role of the lung microbiome as a biomarker for identifying and predicting the prognosis of VAP. However, research on the respiratory microbiome in individuals with VAP caused by carbapenem-resistant Acinetobacter baumannii (CRAB) remains limited. Therefore, we aimed to analyze the respiratory microbiome of patients with CRAB VAP. Respiratory specimens were collected from patients who developed CRAB VAP. Microbiome diversity and composition were analyzed using 16S rRNA gene pyrosequencing. Patients were categorized into two groups based on mortality outcomes: intensive care unit (ICU) mortality or 28-day mortality after ICU discharge. Twenty patients with CRAB VAP were enrolled, including nine in the mortality group. No significant differences were observed in α-diversity indices between the study groups. However, multivariable Firth’s logistic regression revealed a significant association between a relative abundance of the Enterococcus genus ≥ 1% and mortality outcomes (odds ratio: 0.06; 95% confidence interval: 0.00–0.771; p = 0.029). This study characterized the respiratory microbiome of patients with CRAB VAP and highlighted the potential role of microbiome analysis in predicting disease prognosis. Further studies with larger sample sizes are warranted to validate these findings.
- Open Access
Hepatitis B Reactivation and Vaccination Effectiveness after Solid Organ Transplantation: A Matched Case-Control Study
Solid organ transplant (SOT) recipients are at significant risk of hepatitis B (HB) virus (HBV) reactivation (HBVr). Despite the clinical significance of HBVr after solid organ transplantation, data on the risk factors for HBVr and vaccine effectiveness in SOT recipients with resolved HBV infection are limited. This study evaluated the risk factors for HBVr and the seroconversion rates after HBV vaccination in SOT recipients. Patients who had undergone solid organ transplantation and those with a resolved HBV infection were identified. We matched patients who experienced post-transplantation HBVr with those who did not. We also explored the characteristics and seroconversion rates of HBV-vaccinated patients following transplantation. In total, 1299 SOT recipients were identified as having a resolved HBV infection at the time of transplantation. Thirty-nine patients experienced HBVr. Pre-transplant HB surface antibodies (anti-HBs) positivity and allograft rejection within 3 months after transplantation were independently associated with HBVr. Among the 17 HBV-vaccinated patients, 14 (82.4%) received three or fewer vaccine doses, and 13 (76.5%) had seroconversion with positive anti-HBs results. Pre-transplant anti-HBs(−) status and allograft rejection were risk factors for HBVr in SOT recipients with a resolved HBV infection, and HBV vaccination after transplantation resulted in a high rate of anti-HBs seroconversion. HBV vaccination after transplantation should be considered to reduce the HBVr risk.
Open AccessHepatitis B Reactivation and Vaccination Effectiveness after Solid Organ Transplantation: A Matched Case-Control Study
Solid organ transplant (SOT) recipients are at significant risk of hepatitis B (HB) virus (HBV) reactivation (HBVr). Despite the clinical significance of HBVr after solid organ transplantation, data on the risk factors for HBVr and vaccine effectiveness in SOT recipients with resolved HBV infection are limited. This study evaluated the risk factors for HBVr and the seroconversion rates after HBV vaccination in SOT recipients. Patients who had undergone solid organ transplantation and those with a resolved HBV infection were identified. We matched patients who experienced post-transplantation HBVr with those who did not. We also explored the characteristics and seroconversion rates of HBV-vaccinated patients following transplantation. In total, 1299 SOT recipients were identified as having a resolved HBV infection at the time of transplantation. Thirty-nine patients experienced HBVr. Pre-transplant HB surface antibodies (anti-HBs) positivity and allograft rejection within 3 months after transplantation were independently associated with HBVr. Among the 17 HBV-vaccinated patients, 14 (82.4%) received three or fewer vaccine doses, and 13 (76.5%) had seroconversion with positive anti-HBs results. Pre-transplant anti-HBs(−) status and allograft rejection were risk factors for HBVr in SOT recipients with a resolved HBV infection, and HBV vaccination after transplantation resulted in a high rate of anti-HBs seroconversion. HBV vaccination after transplantation should be considered to reduce the HBVr risk.